Anaplastic large cell lymphoma treated with a leukemia-like therapy: Report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol

Cancer

Volumn 104, Issue 10, 2005, Pages 2133-2140

  Rosolen, Angelo ^a   Pillon, Maria ^a   Garaventa, Alberto ^b   Burnelli, Roberta ^c   D'Amore, Emanuele S ^d   Giuliano, Maria ^e   Comis, Margherita ^f   Cesaro, Simone ^a   Tettoni, Katia ^g   Moleti, Maria Luisa ^h   Tamaro, Paolo ⁱ   Visintin, Gianluca ^a   Zanesco, Luigi ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Azienda Ospedaliera di Reggio Calabria   (Italy)

^g Clinica Pediatrica   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

Anaplastic large cell lymphoma; Child; LSA2 L2; Outcome; Therapy

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

ADULT; AGED; ALLERGY; ANAPLASTIC CARCINOMA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL ARTICLE; FEMALE; HUMAN; ITALY; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; OUTCOMES RESEARCH; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REMISSION; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LYMPHOMA, LARGE-CELL; MALE; METHOTREXATE; NEOPLASM STAGING; PREDNISONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 27644463079     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21438     Document Type: Article

References (30)

1. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
2. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292-293.
3. Harris NL, Jaffe ES, Stein H, et al. Revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
4. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695.
5. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol. 1998;153:875-886.
6. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001;114:741-760.
7. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol. 2001;14:219-228.
8. Rimokh R, Magaud JP, Berger F, et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is a characteristic of anaplastic large cell lymphoma (ki-1 lymphoma). Br J Haematol. 1989;71:31-36.
9. Downing JR, Shurtleff SA, Zielenska M, et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase- polymerase chain reaction. Blood. 1995;85:3416-3422.
10. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM) -ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89:1394-1404.
11. Liang X, Meech SJ, Odom LF, et al. Assessment of t(2;5)(p23; q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am J Clin Pathol. 2004;121:496-506.
12. Delsol G, Al Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol. 1988; 130:59-70.
13. Wright D, McKeever P, Carter R. Childhood non Hodgkin lymphomas in the United Kingdom: findings from the UK Children's Cancer Study Group. J Clin Pathol. 1997;50:128-134.
14. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 4th ed. Philadelphia: J.B. Lippincott, 2002.
15. Sandlund JT, Pui CH, Roberts WM, et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood. 1994;84:2467-2471.
16. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Münster group studies. J Clin Oncol 1994;12:899-908.
17. Brugières L, Le Deley MC, Pacquement H, et al. CD 30+ anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591-3598.
18. Abdulkader I, Cameselle-Teijeiro J, Fraga M, Rodriguez-Nunez A, Allut AG, Forteza J. Primary anaplastic large cell lymphoma of the central nervous system. Hum Pathol. 1999; 30:978-981.
19. Vecchi V, Burnelli R, Pileri S, et al. Anaplastic large cell lymphoma (Ki-1 + /CD30+) in childhood. Med Pediatr Oncol. 1993;21:402-410.
20. Massimino M, Gasparini M, Giardini R. Ki-1 (CD30) anaplastic large-cell lymphoma in children. Ann Oncol. 1995;6:915-920.
21. Mora J, Filippa DA, Thaler HT, et al. Large cell non-Hodgkin lymphoma of childhood: analysis of 78 consecutive patients enrolled in 2 consecutive protocols of the Memorial Sloan-Kettering Cancer Center. Cancer. 2000;88:186-197.
22. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 2001;97:3699-3706.
23. Williams DM, Hobson R, Imeson J, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117:812-820.
24. Wollner N. Non-Hodgkin's lymphoma in children; diffuse lymphoblastic histology; diffuse non-lymphoblastic histology; LSA2-L2 experience. An Esp Pediatr. 1988;29(Suppl 34):122-126.
25. Murphy SB. Classification, staging and results of treatment of childhood non-Hodgkin's lymphoma: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332-339.
26. Lopez-Andrew JA, Ferris J, Verdeguer A, Esquembre C, Senent ML, Castel V. Secondary acute promyelocytic leukemia in a child treated with epipodophyllotoxins. Am J Pediatr Hematol Oncol. 1994;16:384-386.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
28. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A. 1972;135:185-198.
29. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23:541-547.
30. Brugieres L, Le-Deley MC, Pacquement H, et al. Relapses of of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann Oncol. 2000;11:53-58.